No. 10, October 2007 

CASE STORY

TopoTarget Ready to Launch Totect in the US

TopoTarget is the first Danish biotech company in Medicon Valley that has been granted FDA approval for marketing a new indication treatment in the US. Totect is due for launch on the US market in October 2007. Peter Buhl Jensen, CEO of TopoTarget, has high expectations for the product. Using the experience gained by the company from the launch of Savene in Europe in 2006, TopoTarget has worked hard to prepare the market for the launch of Totect and has built its own sales force in the US. Read more

 

PROJECT NEWS

Health Economy and Incontinence in Bladder Academy

Health economy was the topic for the workshop held two weeks ago by MVA Bladder Academy. It was decided to continue and strengthen the health economy track in Bladder Academy, more specifically within the area of incontinence. The focus of the project will be the cost of incontinence in general, and how different measures can change the costs for incontinence patients in health budgets, municipal budgets and for society in general.

Do you have a particular interest in this area? Contact Project Manager Tove Østergaard at to@mva.org or phone +45 35 32 41 54. Read more

Medicon Valley Life Science Tour and Competition

As part of the MVA 10 year anniversary, 50 high school students from Medicon Valley were invited on a guided one-day tour to explore the biotech industry in Medicon Valley. The purpose of the tour was to captivate the students' interest in life science.

- At first I was not quite sure whether to participate, but now I realise that biotech is the future, commented a student from Sorø Akademi in Denmark.

Moreover, the tour served as inspiration for the ongoing Medicon Valley Life Science Essay Competition. Read more

MVA 10 year Jubilee

MVA is looking forward to celebrating our 10 year anniversary on 30 October with our members and stakeholders. Underpinning the theme Regional Excellence and Global Challenges, prominent speakers will speak on world-class research and entrepreneurs in Medicon Valley. Moreover, the winner of the Medicon Valley Life Science Essay Competition will be announced. Read the full programme here.

Pharma meets Biotech - Biotech meets Pharma

One-on-one meetings, plenum sessions, company presentations and other network opportunities. International big pharma and Medicon Valley biotech companies and investors will meet in Copenhagen 11 December 2007 at Medicon Valley International Partnering Event 2007: "Pharma meets Biotech - Biotech meets Pharma". Registration has now opened. Read more 

 

 

INTERNATIONAL VISITS

Korean Delegation: Building up an Organisation - How it is Done

On 25 September MVA was visited by a delegation from the department of strategic Planning - Ministry of Planning and Budget of the Republic of Korea. The delegation was interested in learning similar cluster organisation in Korea. Read more 

Portuguese Delegation: Studies on Cluster Development

On 21 September MVA hosted a high level delegation of policy makers, academics and business people from the northern Munho region of Portugal. The Task Force is developing a cluster strategy for the biomedical and health related services in Portugal. At the top of their agenda for their visit, was their meeting with MVA to discuss issues related to MVA's role in the region. Read more

NEWS FROM MEDICON VALLEY

US Government Extends RFP-2 Contract with Bavarian Nordic

The US government has extended the RFP-2 contract that was awarded to Bavarian Nordic in 2004. Within the scope of the extension, Bavarian Nordic will initiate a larger Phase II study with IMVAMUNE in people diagnosed with atopic dermatitis. Read more

High Level of Scientific Research in Medicon Valley

A new analysis of the most quoted scientific articles with Danish participation emphasises the high level of scientific research in the Medicon Valley region. Three universities from Medicon Valley are highlighted in the analysis. Read more

Probi Agreement Opens American Market for Health Foods

Probi has signed a license agreement with NextFoods for the American market regarding the launch of a functional food product containing Probi's probiotics. Probi is guaranteed a royalty of USD 1.5 million in 2008-2009. Read more

Danish Scientist Awarded 1st Prize for Research in the Field of COPD

Dr Morten Dahl from Herlev University Hospital, Denmark, is this year's winner of the European Respiratory Society's annual award for research in the field of Chronic Obstructive Pulmonary Disease. Read more

Novo Nordisk Rated Supersector Leader

The Dow Jones Sustainability indexes ranks Novo Nordisk as best in its class in terms of sustainability in the pharmaceutical industry. Lise Kingo, Executive Vice President at Novo Nordisk comments that the ranking as the leading company regarding sustainability is well in line with the results Novo Nordisk has achieved. Read more

Clinical Trials Update

Read the updates on clinical trials performed by Medicon Valley companies from week 38 and week 40.

 

 

OTHER NEWS

Subscribe to the MVA Calendar Service

The newsletter sections ‘Activities in Medicon Valley' and ‘International Activities' are no longer included in the MVA Newsletter. Instead, they are listed in the MVA Calendar Service, which every second week provides you with an overview of life science events and activities in Medicon Valley and internationally. To keep updated, please subscribe to the MVA Calendar Service. 
  

NEW MEMBERS

BioPorto

BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease both for the benefit of individual patients and to promote efficiency in the health sector. The company's developments include a test (NGAL) to diagnose and monitor acute kidney damage. BioPorto was founded in 2000 and has 25 employees. BioPorto is owned by a group of shareholders, and the company's B shares are listed on OMX Nordic Exchange Copenhagen (BIOP B).

Contacts: www.bioporto.com - info@bioporto.com - (+45) 45 29 00 29

Composite

Composite A/S is a Danish software company founded in 1999. We develop and sell Content Management Systems. The MVA Newsletter and the website www.mva.org are based on Composite, and with a costumer reference list that includes Novo, Bavarian Nordic, World Diabetes Foundation and Pharmakon, to name but a few, we have considerable experience in servicing companies in the Medical and Pharmaceutical industry.

Contacts: www.composite.net - info@composite.net - (+45) 39 15 76 00

Krogh and Co.

Krogh & Co. is a Copenhagen based graphic design agency. We help companies and organizations sharpen their corporate profile and branding strategy - i.e. visual identity (essential design), brochures, product sheets, packaging, ads, etc. Krogh & Co. has extensive experience with the life science industry and has recently developed MVA's new visual identity with logo and paper line. The logo signals that MVA is an extensive collective body in constant motion, and the colors reveal MVA's Scandinavian legacy.

Contact: www.krogh.dk - info@krogh.dk - (+45) 32 64 20 30

Qlucore AB

Qlucore provides software solutions for interactive analysis and visualization of large data sets, from Microarrays or other types, including financial data with up to 100 million samples. The software enables researchers and users to find structures and patterns in their data sets. All work is carried out on a normal PC and the results of filtering are shown instantly in 3D plots which the user can turn and rotate. A solution cornerstone is an innovative use of Principal Component Analysis (PCA) algorithms.

Contact: www.qlucore.com - sales@qlucore.com - (+46) 46 286 3110

MEDIA NEWS

Life Science Clusters

The latest issue of Life Science Clusters was published in September. Read the online journal here.

Mandag Morgen Elite #15

The Danish think tank Mandag Morgen (Monday Morning) has published a business analysis that presents Europe's ten most innovative biotech companies. Medicon Valley company, TopoTarget, is to be found in the top ten list which is based on the Ernst and Young Global Biotechnology Report 2007.